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During the past decade, the morbidity and
mortality from adult asthma have been
increasing. Consequently, identifying modi-
fiable environmental factors that exacerbate
asthma has become a priority. Limited evi-
dence indicates that exposure to environ-
mental tobacco smoke (ETS) may exacerbate
asthma among adults (1–4). Further research
is necessary to establish the causal connec-
tion between ETS exposure and adverse
asthma health outcomes in adults. To eluci-
date the effects of ETS better, we developed
a survey instrument to measure ETS expo-
sure in a cohort of adults with asthma living
in northern California. 
Previous questionnaires have been
designed to assess ETS exposure, but they
have limitations for studying the effect of
ETS exposure on asthma health status in
adults. The validation of most previous ETS
questionnaire instruments occurred in places
and times at which cigarette smoking was
more common. Consequently, their utility in
California, where the prevalence of smoking
currently is substantially lower than in
most other states, is unclear (5). Since
most previous ETS survey instruments
have been published, California state law
has prohibited smoking in nearly all work-
places effective 1 January 1995 (6). This
change may have affected the locations of
ETS exposure, including a shift in indoor
workplace exposure to outdoor locations.
Moreover, previous instruments have not
ascertained asthma-related ETS effects,
such as respiratory symptoms and medica-
tion use. To study the effects of ETS on
adults with asthma living in northern
California, we developed a survey instru-
ment that measures exposure in relevant
microenvironments, including outdoor
workplaces.
Another limitation of previous studies is
validation using serum, urine, or salivary
cotinine, a nicotine metabolite and bio-
marker of ETS exposure (7–16). Because it
has substantial person-to-person variability
due to uptake, metabolism, and elimination,
cotinine has limitations as a biomarker of
ETS exposure (17). Cotinine is also found in
several foods, reducing its specificity for ETS
when exposure levels are very low (17,18).
The half-life of cotinine is relatively short
(1–2 days), which limits its utility for assess-
ing exposure during a longer period. To vali-
date the ETS exposure survey instrument,
we used a passive badge monitor that mea-
sures actual exposure to ambient nicotine, a
more direct and specific measure of personal
ETS exposure (19,20).
Materials and Methods
Overview. We developed a survey instru-
ment to measure ETS exposure among
adults with asthma living in northern
California. To validate the instrument, we
recruited 50 subjects from an ongoing longi-
tudinal asthma cohort study who had a posi-
tive screening question for ETS exposure or
potential exposure. Each subject wore a pas-
sive nicotine badge monitor for 7 days. After
the personal monitoring period, we read-
ministered the ETS exposure survey instru-
ment. The study was approved by the
University of California San Francisco
Committee on Human Research.
Subject recruitment. We used data col-
lected during an ongoing prospective, longi-
tudinal cohort study of adults with asthma
recruited from physician practices in north-
ern California. Details of recruitment have
been reported previously (21–23). In brief,
we initially recruited subjects from a random
sample of board-certified internal medicine
and pulmonary specialists, internal medicine
and allergy/immunology specialists, and
family practice specialists. The present study
eligibility is based on follow-up interviews
conducted between July 1998 and December
1999, which included 402 subjects. 
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Articles
Because the morbidity and mortality from adult asthma have been increasing, the identification of
modifiable environmental exposures that exacerbate asthma has become a priority. Limited evi-
dence suggests that exposure to environmental tobacco smoke (ETS) may adversely affect adults
with asthma. To study the effects of ETS better, we developed a survey instrument to measure
ETS exposure in a cohort of adults with asthma living in northern California, where public
indoor smoking is limited. To validate this survey instrument, we used a passive badge monitor
that measures actual exposure to ambient nicotine, a direct and specific measure of ETS. In this
validation study, we recruited 50 subjects from an ongoing longitudinal asthma cohort study who
had a positive screening question for ETS exposure or potential exposure. Each subject wore a
passive nicotine badge monitor for 7 days. After the personal monitoring period, we readminis-
tered the ETS exposure survey instrument. Based on the survey, self-reported total ETS exposure
duration ranged from 0 to 70 hr during the previous 7 days. Based on the upper-range boundary,
bars or nightclubs (55 hr) and the home (50 hr) were the sites associated with greatest maximal
self-reported exposure. As measured by the personal nicotine badge monitors, the overall median
7-day nicotine concentration was 0.03 µg/m3 (25th–75th interquartile range 0–3.69 µg/m3).
Measured nicotine concentrations were highest among persons who reported home exposure
(median 0.61 µg/m3), followed by work exposure (0.03 µg/m3), other (outdoor) exposure (0.025
µg/m3), and no exposure (0 µg/m3; p = 0.03). The Spearman rank correlation coefficient between
self-reported ETS exposure duration and directly measured personal nicotine concentration dur-
ing the same 7-day period was 0.47, supporting the survey’s validity (p = 0.0006). Compared to
persons with no measured exposure, lower-level [odds ratio (OR) 1.9; 95% confidence interval
(CI), 0.4–8.8] and higher-level ETS exposures (OR 6.8; 95% CI, 1.4–32.3) were associated with
increased risk of respiratory symptoms. A brief, validated survey instrument can be used to assess
ETS exposure among adults with asthma, even with low levels of exposure. This instrument could
be a valuable tool for studying the effect of ETS exposure on adult asthma health outcomes. Key
words: asthma, biological markers, environmental monitoring, nicotine, smoking, tobacco smoke
pollution. Environ Health Perspect 109:809–814 (2001). [Online 13 August 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p809-814eisner/abstract.html
We included the newly developed ETS
exposure survey instrument in structured
telephone interviews. Subjects with no cur-
rent personal tobacco smoking and a positive
answer to any screening question indicating
potential ETS exposure were eligible for the
validation study (n = 235). The screening
questions assessed residence with a smoker
and ETS exposure during the previous 7
days at home, another person’s home, work,
car or other vehicle, bars and nightclubs, and
other locations. We enrolled 50 sequential
subjects who agreed to participate in the val-
idation study, which included wearing the
personal nicotine badge monitor for 7 days
and then completing a second telephone
administration of the ETS survey instru-
ment. Structured telephone interview
content also included demographic charac-
teristics, asthma history, asthma-specific
severity and quality of life (24–26), environ-
mental exposures, health status (SF-12) (27),
and health care utilization for asthma.
As shown in Table 1, there were no sta-
tistical differences in demographic character-
istics or smoking status between participants
(n = 50) and nonparticipants (n = 185) who
had indicated potential ETS exposure at the
initial interview. Compared to nonpartici-
pants, participants had somewhat worse SF-
12 physical component summary scores
(41.7 vs. 46.5, p = 0.007) and severity-of-
asthma scores (10.7 vs. 9.2, p = 0.09).
Conversely, SF-12 mental component sum-
mary scores were slightly better among par-
ticipants (47.2 vs. 44.6, p = 0.04). There
were no statistical differences in asthma-spe-
cific quality-of-life scores. At the initial
interview, self-reported duration of ETS
exposure during the previous 7 days was
similar for participants and nonparticipants
(p = 0.33). Because of study logistics, the
median interval between initial interview
and subsequent validation interview was
225 days (25th–75th interquartile range
138–311 days).
ETS exposure survey instrument. We
designed a survey instrument to measure
recent ETS exposure among adults with
asthma living in northern California (survey
included in Appendix). The instrument
assesses exposure during the previous 7 days
in six microenvironments: the respondent’s
home, another person’s home, traveling in a
car or another vehicle, workplace, bars and
nightclubs, and other locations. For home
exposure, the survey assesses both residence
with a smoker and duration of exposure dur-
ing the previous 7 days (in hours). For each
microenvironment, a screening question
elicits exposure during the previous 7 days.
If there was no exposure, the remaining loca-
tion-specific items are skipped. Given the
workplace smoking restrictions in California,
the instrument specifically ascertains expo-
sure in the most likely work-related loca-
tions: outdoor smoking areas at work and
outdoor job duties. In each area, the instru-
ment ascertains the total duration (in hours)
of exposure during the previous 7 days and
the intensity of exposure, as indicated by the
presence of tobacco smoke odor or visible
smoke. In each location, we also assessed
exposure-related sensory irritation symptoms
(eye and nose irritation) and potential
asthma-related respiratory symptoms
(coughing, wheezing, or chest tightness).
Furthermore, the instrument ascertains
whether the subject used extra metered-dose
inhaler asthma medications after ETS expo-
sure during the same period. 
Personal nicotine badge monitors. Each
subject was instructed to wear the personal
nicotine badge monitor during regular
activities for 7 days. The passive monitor,
which has been described previously
(19,20), samples nicotine from ambient air.
A 4-cm diameter polystyrene cassette holds a
filter treated with sodium bisulfate and a
membrane filter functions as a windscreen.
Ambient nicotine diffuses to the treated fil-
ter, where it is trapped. The collected nico-
tine is analyzed by gas chromotography with
nitrogen selective detection. From the
amount of nicotine measured on the filter
(micrograms), which represents the total
amount of nicotine collected during the
monitoring period, we calculated the nico-
tine concentrations by dividing the nicotine
collected by the estimated volume of air
sampled (monitoring duration multiplied by
sampling rate of 24 mL/min). The passive
monitors have a limit of detection < 0.01 µg
per filter and a coefficient of variability of
0.11 for replicate analysis (20). We included
two control badges (field blanks), which
revealed no detectable nicotine.
Statistical analysis. We analyzed the data
using SAS version 6.12 (SAS Institute, Cary,
NC). We performed bivariate analysis using
the chi-square test for categorical variables, t-
test for continuous normally distributed
variables, and Wilcoxon rank-sum test for
non-normally distributed, continuous vari-
ables. Because self-reported duration of ETS
exposure and measured nicotine concentra-
tion were non-normally distributed, we
report the median values, range, and
interquartile range.
To validate the ETS exposure instru-
ment, we calculated the Spearman rank
correlation between total self-reported
hours of exposure in all locations with the
nicotine concentration measured by per-
sonal badge monitoring. In addition to this
primary analysis, we tested two alternative
scoring systems defined a priori. First, we
calculated an ETS exposure score weighted
for exposure intensity. For each location of
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Table 1. Baseline characteristics of subjects participating in personal nicotine badge monitor study compared with other subjects from the asthma cohort.
Subject group
ETS exposure, ETS exposure, p-Value for
No ETS exposure nonparticipant badge participant participant
Variable (n = 167) (n = 185)a (n = 50) vs. nonparticipant
Demographic characteristics
Age (mean years, SD) 45.0 (7.4) 43.1 (7.8) 44.4 (7.9) 0.30
Sex (% female) 121 (72) 128 (69) 36 (72) 0.70
Race/ethnicity (% white, non-Hispanic) 133 (80) 120 (65) 36 (72) 0.34
Income (median $, 25th–75th IQR) 62,500 (35,000–87,500) 45,000 (35,000–87,500) 62,500 (31,250–87,500) 0.95
Ever smoked cigarettes (%) 70 (42) 63 (34) 15 (30) 0.59
Currently smoke cigarettes (%) 27 (16) 0 0 —
Asthma severity/health status
Severity-of-asthma score 9.2 (5.3) 9.2 (5.1) 10.7 (6.8) 0.09
Asthma quality-of-life score 15.3 (14.9) 16.3 (13.8) 18.8 (16.0) 0.27
SF-36 physical summary score 45.8 (12.1) 46.5 (10.7) 41.7 (12.2) 0.007
SF-36 mental summary score 45.4 (7.7) 44.6 (8.3) 47.2 (7.2) 0.04
ETS exposure
Duration of exposure, past 7 days 0 (0–0) 0 (0–1) 0 (0–2) 0.33
(median, 25th–75th IQR)b
IQR, interquartile range. All data are mean (SD) unless otherwise indicated. 
aA positive answer to a screening question for each location: home, other person’s home, work, car or vehicle, bar or nightclub, or other location. bBased on initial interview.
exposure, we weighted exposure duration by
130% for reported tobacco smoke odor and
150% for visible smoke. Second, we calcu-
lated an ETS exposure score weighted for
sensory irritation and respiratory symptoms
(1 point added for each symptom). 
To evaluate exposure stability over
time, we compared the self-reported dura-
tion of ETS exposure during the previous 7
days at the initial and validation telephone
interviews. Because duration of exposure
was not normally distributed, we performed
a rank transformation and then used analy-
sis of variance to calculate the intraclass
correlation.
To validate the questions assessing self-
reported ETS-attributed symptoms and extra
asthma medication use, we used logistic
regression analysis to examine the cross-sec-
tional relation between personal nicotine
exposure and the risk of sensory irritation
symptoms, respiratory symptoms, and extra
inhaled asthma medication use. We created
indicator variables to reflect lower and higher
levels of exposure, which we divided at the
median nicotine concentration for subjects
with measurable exposure. We tested linear
exposure–response relationships by creating
an ordinal predictor variable coding the three
nicotine concentration categories (none,
lower, and higher). We also tested quadratic
exposure–response relationships.
Results
ETS exposure and measured nicotine con-
centration. At the initial interview, 45 of 50
participants reported at least 1 hr of ETS
exposure during the previous 7 days, and five
additional subjects indicated potential ETS
exposure, indicated by residence with a
smoker. At the validation interview per-
formed at completion of personal nicotine
monitoring, most subjects who initially
reported exposure or potential exposure indi-
cated a least 1 hr of ETS exposure (38 of 50,
76%; Table 2). A greater proportion of sub-
jects who reported > 1 hr of ETS exposure at
initial interview reported recent exposure at
validation interview (37 of 45, 82%). 
Of subjects reporting exposure at vali-
dation interview, the proportion with
indoor exposure and outdoor exposure
were comparable (53% and 47%). Of the
20 subjects with indoor exposure, 12 per-
sons also indicated outdoor exposure
(60%). The workplace was the major site
of exposure (38%), followed by “other”
locations, which were all outdoors, and
home (14%). All subjects with workplace
exposure reported recent exposure in an
outdoor smoking area at work, whereas
only one subject also reported outdoor
exposure during work duties.  Only a
minority of subjects who lived with a
smoker reported any domestic ETS expo-
sure during the previous 7 days (6 of 17
persons, 35%). Conversely, nearly all sub-
jects who had no smoking cohabitants
indicated no recent home ETS exposure
(32 of 33 persons, 97%). 
Table 3 shows the proportion of sub-
jects exposed in each of six microenviron-
ments evaluated by the questionnaire
instrument and self-reported exposure dura-
tion. Exposure duration ranged from 0 to
70 hr during the previous 7 days. Based on
the upper range boundary, bars or night-
clubs (55 hr) and the home (50 hr) were the
sites associated with greatest maximal self-
reported exposure in the previous 7 days. 
As measured by the personal nicotine
badge monitors, the overall median 7-day
nicotine concentration was 0.03 µg/m3
(25th–75th interquartile range 0–3.69
µg/m3; Table 4). The measured nicotine
concentration varied significantly by self-
reported exposure location. Compared with
subjects indicating no ETS exposure
(median 0 µg/m3), persons with outdoor
exposure (median 0.03 µg/m3) and indoor
exposure (0.05 µg/m3) had progressively
higher levels (p = 0.03; Table 4). Of note,
more than half of subjects who reported
outdoor exposure only had detectable nico-
tine levels. Measured nicotine concentra-
tions were highest among persons who
reported home exposure (median 0.61
µg/m3), followed by work exposure (0.03
µg/m3), other (outdoor) exposure (0.025
µg/m3), and no exposure (0 µg/m3; p =
0.03). 
Survey instrument validity. To assess
validity, we compared the measurements of
ETS exposure based on the survey instru-
ment and the passive badge monitors (Table
5). The Spearman rank correlation coeffi-
cient between self-reported ETS exposure
duration and directly measured personal
nicotine concentration during the same 7-
day period was 0.47, indicating moderate
agreement (p = 0.0006). The exposure scores
adjusting for exposure intensity and expo-
sure intensity plus sensory irritation and res-
piratory symptoms did not improve the
correlation (Table 5). Excluding subjects
with no measurable nicotine concentration
did not affect these results appreciably. To
examine the stability of recent ETS exposure
over time, we compared the self-reported
total hours of ETS exposure ascertained dur-
ing the validation interview with the initial
interview. The intraclass correlation was
0.72, indicating moderate to high stability
over time.
ETS exposure and the risk of symptoms.
To evaluate the validity of self-reported
ETS-attributed symptoms, we examined the
cross-sectional relation between directly
measured personal nicotine concentration
and the risk of sensory irritation symptoms,
respiratory symptoms, and medication use.
Compared to persons with no measured
exposure, lower-level and higher-level ETS
exposures were associated with increased risk
of sensory symptoms, including eye, nose,
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Table 2. Prevalence of self-reported ETS expo-
sure among 50 subjects in ETS badge study.
Location Number Prevalence (%)
No exposure 12 24
Any exposure 38 76
Indoor/outdoor
None 12 24
Indoora 20 40
Outdoor only 18 36
Work/home
None 12 24
Work only 19 38
Home only 5 10
Both home and work 2 4
Other only 12 24
Based on questionnaire administered after monitoring
period (validation interview).
aIncludes 12 subjects with both indoor and outdoor expo-
sure.
Table 3. ETS exposure by location among 50 adults with asthma.
Exposure intensity among exposed subjects
No. exposed during Exposure duration during past 7 days (hr) No. who smelled No. who saw
Location past 7 days (%) Minimum Median Mean Maximum smoke (%) smoke (%)
Home 7 (14) 0 0 2.3 50 6 (86) 6 (86)
Other person’s home 8 (16) 0 0 0.3 8 8 (89) 3 (33)
Car or vehicle 6 (12) 0 0 0.5 20 N/A N/A
Work—outdoor smoking areaa 21 (42) 0 3 5.5 40 17 (63) N/A
Bar or nightclub 5 (10) 0 0 1.3 55 N/A 3 (60)
Otherb 12 (24) N/A N/A N/A N/A N/A N/A
Total 38 (76) 0 0 4.6 70 24 (48) 10 (20)
N/A, not asked.
aNumber of times walked through smoking area (not hours of exposure). bAll were outdoor sites.
and throat irritation [odds ratio (OR) 2.2
and 5.9, respectively; Table 6]. Lower- and
higher-level ETS exposures also were related
to an increased risk of respiratory symptoms
(OR 1.9 and 6.8) and extra bronchodilator
use after ETS exposure (OR 2.2 and 8.1).
For all three outcomes, there was statistical
evidence of a simple exposure–response rela-
tion (p = 0.054, 0.017, and 0.022, respec-
tively). There was no evidence of a quadratic
exposure–response relation (p > 0.5 in all
cases).
Discussion
We developed an ETS exposure instrument
that is brief and easy to administer by tele-
phone interview. The ETS questionnaire
can be incorporated easily into a larger sur-
vey instrument. Self-reported total hours of
ETS exposure during the previous 7 days
correlated moderately with measured nico-
tine concentration, supporting the instru-
ment’s validity. More complex scoring
systems that incorporate intensity of expo-
sure or intensity plus respiratory and sensory
irritation symptoms do not appreciably
improve instrument validity. Exposure
monitoring also supported the validity of
self-reported ETS-attributed symptoms and
medication use. ETS exposure, measured by
the personal nicotine badge, was associated
with a greater risk of ETS-attributed sensory
irritation symptoms, respiratory symptoms,
and extra medication use.
We found a moderate correlation
between self-reported ETS exposure dura-
tion and direct personal nicotine measure-
ments, consistent with previous studies
that used cotinine as a biomarker (7–16).
Fewer studies have used personal nicotine
monitoring, which measures actual expo-
sure, to validate questionnaire instruments.
In a study of 415 pregnant women,
O’Connor and colleagues (28) demon-
strated a similar correlation between total
duration of ETS exposure and nicotine
concentration (r = 0.41). The investigators
cautioned that their results should not be
extrapolated to nonpregnant women, who
may have different patterns of exposure.
Other investigators used a more compli-
cated questionnaire instrument that
assessed duration, intensity, and proximity
of each individual ETS exposure during
the previous week (29). Using personal
nicotine monitoring, they found a higher
correlation with an index of ETS exposure
based on these variables (r = 0.91). This
questionnaire requires subject response
entry in multicell tables that would be dif-
ficult to administer by telephone. 
For most subjects, the observed nico-
tine concentrations were low, with a
median of 0.03 µg/m3 (range 0–3.69
µg/m3). Compared to our study, Coghlin
and colleagues (29) found higher nicotine
concentrations among 53 volunteers who
wore personal monitors during a typical
week (median 1.7 µg/m3 and 2.8 µg/m3 in
two different periods) (29). The observed
concentrations among 50 adults with
asthma were more comparable to those of
pregnant women who reported ETS expo-
sure (median 0.1 µg/m3). Pregnant women
who reported only social exposure had
even lower concentrations (median 0.08
µg/m3). Both pregnant women and adults
with asthma, because of their health condi-
tions, might be expected to limit their ETS
exposure.
Adults with asthma living in northern
California had low levels of ETS exposure,
reflecting the restrictions on public smok-
ing. Moreover, the locations where ETS
exposure occurs appear to be changing.
Residence with a smoker, which has been
used in many epidemiologic studies as a
key marker of ETS exposure (30–32), was
a poor indicator of recent exposure. Only a
minority of adults with asthma who live
with a smoker reported any exposure dur-
ing the previous 7 days,  most l ikely
because smoking was not permitted
indoors. A shift from indoor to outdoor
exposure was also observed, with 38% of
subjects indicating outdoor workplace
exposure. Future ETS exposure survey
instrument should take these temporal
trends into account. 
This validation study is potentially lim-
ited by the low observed exposure levels,
which may have attenuated the correlation
between self-reported exposure and nico-
tine concentration. However, these low
exposure levels reflect current restrictions in
public smoking that require consideration
in epidemiologic studies. Even among per-
sons who may have lower than average ETS
exposure due to their disease, the instru-
ment appears to have adequate validity.
The ETS exposure survey instrument also
measures a 7-day period, which may not be
fully representative of a subject’s usual
exposure. Furthermore, our instrument,
which is adapted for use in California, does
not assess indoor workplace exposure. A
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Table 4. Location of ETS exposure and measured nicotine exposure level.
No. of Nicotine concentration (µg/m3)
Location subjects Median Range 25th–75th IQR p-Valuea
Indoor/outdoor 0.03
None 12 0 0–0.06 0–0.035
Outdoor onlyb 18 0.03 0–0.08 0–0.05
Indoor 20 0.05 0–3.69 0–0.49
Home/work 0.03
None 12 0 0–0.06 0–0.035
Work only 19 0.03 0–0.36 0–0.07
Homec 7 0.61 0–3.69 0.02–3.03
Other location only 12 0.025 0–0.84 0–0.05
Total 50 0.03 0–3.69 0.03–0.06
IQR, interquartile range. 
aKruskall-Wallis test for comparison of nicotine concentration between groups. bSixty-one percent (n = 11/18) of subjects
who reported outdoor exposure only had detectable nicotine levels. cIncludes two subjects with both home and work
ETS exposure.
Table 6. ETS exposure (nicotine level) and the risk of sensory irritation symptoms, respiratory symptoms,
and extra bronchodilator use.
Sensory irritation Respiratory symptoms Extra bronchodilator use
Measured nicotine level n (OR, 95% CI) (OR, 95% CI) (OR, 95% CI)
None (referent) 21 1.0 1.0 1.0
Lower level (0–0.05 µg/m3) 16 2.2 (0.3–15) 1.9 (0.4–8.8) 2.2 (0.3–15)
Higher level (> 0.05 µg/m3) 13 5.9 (0.95–37) 6.8 (1.4–32.3) 8.1 (1.3–50)
p-Value for trend 0.054 0.017 0.022
*Sensory irritation symptoms: eye or nose irritation; respiratory symptoms: cough, wheezing, or dyspnea.
Table 5. Validity of questionnaire measurement of ETS exposure.
Spearman correlation with
Questionnaire-based measure nicotine concentration p-Value
Exposure duration (hours/previous 7 days) 0.47 0.0006
Score adjusted for exposure intensitya 0.46 0.0007
Score adjusted for exposure intensity, sensory 0.45 0.001
irritation symptoms, and respiratory symptomsb
aScore adjusted for exposure intensity had median 1.6, range 0–128, 25th–75th interquartile range 0.7–3.2. bScore
adjusted for exposure intensity, sensory irritation symptoms, and respiratory symptoms had median 1.9, range 0–137,
25th–75th interquartile range 0.8–5.0.
section for indoor work exposure can be
easily added, modeled on those developed
for other microenvironments (available
from the authors). Further research will be
necessary to evaluate the survey in other
environmental settings, such as large indus-
trial workplaces, where building ventilation
may be different. In such settings, tailor-
made survey instruments could be required. 
Validation of the ETS exposure survey
instrument was also limited by measure-
ment of a single marker of ETS exposure.
Because ETS contains more than 4,000
chemical compounds, it is not feasible to
measure all ETS constituents (32,33).
Although nicotine is a highly specific
marker of ETS, it may not always track
with the ETS components responsible for
disease causation or exacerbation. In partic-
ular, the relationship between nicotine con-
centration and other ETS constituents may
be affected by factors such as building ven-
tilation rate and indoor air volume (17,33).
In addition, nicotine may adsorb to indoor
surfaces and be reemitted in the absence of
active smoking, changing its concentration
relative to other ETS constituents (17).
Despite these factors, field studies indicate
that nicotine correlates strongly with other
ETS constituents, including respiratory sus-
pended particles (34,35) and 3-ethenylpyri-
dine (a volatile organic compound unique
to ETS) (34).
Most epidemologic studies of ETS-
related health effects have used self-
reported ETS exposure. All survey-based
methods of ascertaining ETS exposure are
potentially limited by information bias
(i.e., misclassification of exposure). For
example, persons with symptomatic respi-
ratory disease may be more l ikely to
remember and report recent ETS exposure.
In our study of adults with asthma, per-
sonal nicotine badge monitoring was a fea-
sible method for directly measuring ETS
exposure, potentially minimizing this
information bias. 
A brief survey instrument can be used to
assess ETS exposure among adults with
asthma, even with low levels of exposure.
The instrument is valid and can be incorpo-
rated into larger telephone-based interviews.
This instrument could be a valuable tool for
studying the effect of ETS exposure on
adult asthma health outcomes. 
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Appendix
Environmental Tobacco Smoke Questionnaire Instrument 
The next series of questions ask about your exposure to other people’s tobacco smoke. 
Q1. Many people have different approaches to tobacco smoking in their household. Which is the best description
of tobacco smoking in your home? Would you say that:
(1) You never allow smoking inside your home,
(2) Smoking is allowed only in certain rooms, but not in other areas of your living space, or 
(3) Smoking is allowed in all rooms of your home. 
Q2. Do you live in the same household with someone who smokes tobacco products? 
[If yes to Q2] Q3. How many people in your household smoke? 
[If Q1 = 2 or 3 and Q2 = yes] Q4. Has anyone smoked tobacco in your home in the past seven days? 
[If yes to Q4, then ask next series; else skip to Q12]
Q5. In the past 7 days, how many hours in total were you exposed to someone else’s tobacco smoke at home?
Q6. During the past 7 days, did you enter a room in your home that was visibly smoky?
Q7. In the past 7 days, did you smell tobacco smoke in your home? 
You said that you were exposed to someone else’s tobacco smoke in your home. During the past 7 days, 
did you experience any of the following after this exposure:
Q8. Red eyes or eye irritation? 
Q9. Runny nose or nose irritation? 
Q10. Coughing, wheezing, or chest tightness? 
Q11. In the past 7 days, did you take extra asthma sprays after exposure to tobacco smoke in your home?
Q12. In the past 7 days, have you visited another person’s home where someone was smoking
tobacco products indoors? 
[If yes to Q12 then ask next series; else skip to Q20] 
Q13. In the past 7 days, how many hours in total were you exposed to someone else’s tobacco smoke in 
another person’s home?
Q14. During the past 7 days, did you enter a room in another person’s home that was visibly smoky?
Q15. In the past 7 days, did you smell tobacco smoke in another person’s home?
You answered that you were exposed to someone else’s tobacco smoke in another person’s home. During 
the past 7 days, did you experience any of the following after this exposure:
Q16. Red eyes or eye irritation? 
Q17. Runny nose or nose irritation? 
Q18. Coughing, wheezing, or chest tightness? 
Q19. In the past 7 days, did you take extra asthma sprays after exposure to tobacco smoke in another person’s 
home?
Q20. In the past 7 days, have you traveled by car or other vehicle with someone else who was smok-
ing tobacco products?
[If yes to Q20 then ask next series; else skip to Q26] 
Q21. In the past 7 days, how many hours in total did you spend traveling in a car while someone was smok-
ing tobacco?
You answered that you were exposed to someone else’s tobacco smoke while traveling by car. During the 
past 7 days, did you experience any of the following after this exposure:
Q22. Red eyes or eye irritation? 
Q23. Runny nose or nose irritation? 
Q24. Coughing, wheezing, or chest tightness? 
Q25. In the past 7 days, did you take extra asthma sprays after exposure to someone else’s tobacco smoke in a car?
Q26. Is there an outdoor area at your workplace where cigarette smokers routinely gather or congre-
gate in order to smoke?
[If yes to Q26 then ask next series; else skip to Q33]
Q27. In the past 7 days, how many times did you walk through or past this area while others were smoking?
Q28. While walking through or past this area, did you smell smoke? 
In the past 7 days, did walking through or past this area result in your experiencing any of the following:
Q29. Red eyes or eye irritation? 
Q30. Runny nose or nose irritation? 
Q31. Coughing, wheezing, or chest tightness? 
Q32. In the past 7 days, did you take extra asthma sprays after walking through or past this area?
Q33. Do your job duties directly involve working outdoors one or more hours per week? 
[If yes to Q33] Q34. During your work outdoors, do any of your coworkers smoke tobacco products in your presence? 
[If yes to Q34 then ask next series; else skip to Q42]
Q35. In the past 7 days, how many hours did you spend near coworkers who were smoking tobacco outdoors?
Q36. During the past 7 days, did you smell tobacco smoke while working outdoors?
You answered that you were exposed to your coworkers’ tobacco smoke while working outdoors. During the 
past 7 days, did you experience any of the following after this exposure:
Q37. Red eyes or eye irritation? 
Q38. Runny nose or nose irritation? 
Q39. Coughing, wheezing, or chest tightness? 
Q40. In the past 7 days, did you take extra asthma sprays after exposure to tobacco smoke outdoors? 
Q41. In the past 7 days, did you take extra asthma sprays after working outdoors WITHOUT tobacco smoke 
exposure? 
Q42. In the past 7 days or nights, were you in a bar, nightclub, cocktail lounge, sports arena, or con-
cert hall where someone else was smoking tobacco products?
[If yes to Q42 then ask next series; else skip to Q50] 
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Q43. In the past 7 days, how many hours in total were you exposed to someone else’s tobacco smoke in a 
bar or other place of entertainment?
Q44. During the past 7 days, did you enter a room in a bar or other place of entertainment that was visibly smoky?
Q45. In the past 7 days did your clothes smell like tobacco smoke after returning home from a bar or other 
place of entertainment?
You answered that you were exposed to someone else’s tobacco smoke in a bar or other place of entertainment. 
During the past 7 days, did you experience any of the following after this exposure:
Q46. Red eyes or eye irritation? 
Q47. Runny nose or nose irritation? 
Q48. Coughing, wheezing, or chest tightness? 
Q49. In the past 7 days, did you take extra asthma sprays after exposure to tobacco smoke in a bar or other place 
of entertainment?
Q50. I have asked you about exposure to someone else’s tobacco smoke in your home, friends’
homes, work, and bars or nightclubs. In the past 7 days, was there any other location where you were
exposed to tobacco smoke? 
[If yes to Q51 then ask next series; else skip to end] 
Q51. Specify: _________________
During the past 7 days, did you experience any of the following after this exposure:
Q52. Red eyes or eye irritation? 
Q53. Runny nose or nose irritation? 
Q54. Coughing, wheezing, or chest tightness? 
Q55. Did you use extra asthma sprays after exposure to someone else’s tobacco smoke in this place?
Administration and Scoring
Unless otherwise specified, all questions have yes/no response options. For each microenvironment, a screening
question (in bold font) ascertains whether any ETS exposure occurred during the past 7 days. If the subject indi-
cates ETS exposure in that environment, then a series of questions assess duration of exposure, exposure inten-
sity, and symptoms/asthma medication use. Otherwise, the survey skips to the next microenvironment screening
question.
To determine the total duration of exposure during the past 7 days, sum the individual microenvironment
exposure durations (Q5 + Q13 + Q21 + Q35 + Q43). An ETS exposure score weighted for exposure intensity can
also be calculated. For each location of exposure, we weighted exposure duration by 130% for reported tobacco
smoke odor and 150% for visible smoke. A second ETS exposure score weighted for sensory irritation and respi-
ratory symptoms is calculated by further adding 1 point added for each symptom. 
